BR112023000212A2 - Éter macrocíclico contendo derivados de indol como inibidores de mcl-1 - Google Patents

Éter macrocíclico contendo derivados de indol como inibidores de mcl-1

Info

Publication number
BR112023000212A2
BR112023000212A2 BR112023000212A BR112023000212A BR112023000212A2 BR 112023000212 A2 BR112023000212 A2 BR 112023000212A2 BR 112023000212 A BR112023000212 A BR 112023000212A BR 112023000212 A BR112023000212 A BR 112023000212A BR 112023000212 A2 BR112023000212 A2 BR 112023000212A2
Authority
BR
Brazil
Prior art keywords
mcl
inhibitors
ether containing
indol derivatives
macrocyclic ether
Prior art date
Application number
BR112023000212A
Other languages
English (en)
Inventor
Christian Albert Ghislain De Boeck Benoit
Jacobus Johannes Antonius Buijnsters Petrus
Ferrer Cabrera Sofia
Peschiulli Aldo
Reuillon Tristan
Jan Rita Rombouts Frederik
Velter Adriana-Ingrid
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112023000212A2 publication Critical patent/BR112023000212A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Abstract

ÉTER MACROCÍCLICO CONTENDO DERIVADOS DE INDOL COMO INIBIDORES DE MCL-1. A presente invenção refere-se a agentes farmacêuticos úteis para terapia e/ou profilaxia em um indivíduo, composição farmacêutica compreendendo tais compostos e seu uso como inibidores de MCL-1, úteis para o tratamento de doenças como câncer.
BR112023000212A 2020-07-08 2021-07-08 Éter macrocíclico contendo derivados de indol como inibidores de mcl-1 BR112023000212A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20184729 2020-07-08
PCT/EP2021/069037 WO2022008674A1 (en) 2020-07-08 2021-07-08 Macrocyclic ether containing indole derivatives as inhibitors of mcl-1

Publications (1)

Publication Number Publication Date
BR112023000212A2 true BR112023000212A2 (pt) 2023-01-31

Family

ID=71833112

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023000212A BR112023000212A2 (pt) 2020-07-08 2021-07-08 Éter macrocíclico contendo derivados de indol como inibidores de mcl-1

Country Status (10)

Country Link
US (1) US20230250109A1 (pt)
EP (1) EP4178677A1 (pt)
JP (1) JP2023532592A (pt)
KR (1) KR20230035621A (pt)
CN (1) CN115776888A (pt)
AU (1) AU2021306644A1 (pt)
BR (1) BR112023000212A2 (pt)
CA (1) CA3184877A1 (pt)
MX (1) MX2023000438A (pt)
WO (1) WO2022008674A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020021648A2 (pt) 2018-05-14 2021-01-26 Gilead Sciences, Inc. inibidores de mcl-1
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
KR20220105661A (ko) 2019-11-26 2022-07-27 길리애드 사이언시즈, 인코포레이티드 Mcl1 억제제를 제조하기 위한 방법 및 중간체
WO2022251247A1 (en) * 2021-05-28 2022-12-01 Zeno Management, Inc. Macrocyclic compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI742074B (zh) 2016-04-22 2021-10-11 瑞典商阿斯特捷利康公司 Mcl-1抑制劑及其使用方法
TW201904976A (zh) 2017-03-31 2019-02-01 瑞典商阿斯特捷利康公司 Ｍｃｌ-１抑制劑及其使用方法
TWI781996B (zh) 2017-03-31 2022-11-01 瑞典商阿斯特捷利康公司 合成ｍｃｌ-１抑制劑之方法
KR20210070312A (ko) 2018-09-30 2021-06-14 지앙수 헨그루이 메디슨 컴퍼니 리미티드 인돌 거대 고리 유도체, 이의 제조 방법, 및 의약에서 이의 응용
CN111205309B (zh) * 2018-11-21 2023-04-07 江苏恒瑞医药股份有限公司 吲哚类大环衍生物、其制备方法及其在医药上的应用
WO2020103864A1 (en) 2018-11-22 2020-05-28 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic indoles as mcl-1 inhibitors

Also Published As

Publication number Publication date
MX2023000438A (es) 2023-02-09
JP2023532592A (ja) 2023-07-28
US20230250109A1 (en) 2023-08-10
AU2021306644A1 (en) 2023-03-09
CA3184877A1 (en) 2022-01-13
CN115776888A (zh) 2023-03-10
EP4178677A1 (en) 2023-05-17
KR20230035621A (ko) 2023-03-14
WO2022008674A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
BR112023000212A2 (pt) Éter macrocíclico contendo derivados de indol como inibidores de mcl-1
BR112022000251A2 (pt) Derivados macrocíclicos de espirociclo como inibidores de mcl-1
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
BR112021009595A2 (pt) Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres
CO2022017049A2 (es) 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer
BR112021025732A2 (pt) Inibidores macrocíclicos de mcl-1
BR112022002532A2 (pt) Compostos heterocíclicos como inibidores de quinase
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19070369A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
SV2010003491A (es) 2- anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
NI201900098A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
BR112012021086A2 (pt) composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112022025117A2 (pt) 2-amino-3-fluoro-but-3-enamidas macrocíclicas como inibidores de mcl-1
BR112019004691A2 (pt) inibidores bicíclicos em espiro da interação menina-mll
BR112023000463A2 (pt) Macrociclos e seu uso
BR112019007863A2 (pt) derivados de naftiridinona inovadores e seu uso no tratamento de arritmia
BR112022009142A2 (pt) Derivados de indol macrocíclicos como inibidores de mcl-1
BR112022009754A2 (pt) Derivados macrocíclicos de sulfonila como inibidores de mcl-1
ECSP22098041A (es) Inhibidores alostéricos de egfr y métodos de uso de estos
BR112023020877A2 (pt) 2-aliltetra-hidrofuranos macrocíclicos como inibidores de mcl-1
BR112022024117A2 (pt) Derivados de 7-pirazol-5-il-indol macrocíclico como inibidores de mcl-1
BR112022025674A2 (pt) Derivados de 7-(pirazol-5-il)-indol macrocíclico n-ligado como inibidores de mcl-1
BR112022025631A2 (pt) Derivados de 4-(pirazol-5-il)-indol macrocíclico n-ligados como inibidores de mcl-1